Skip to main content

Advertisement

Log in

Towards scale-up and regulatory shelf-stability testing of curcumin encapsulated polyester nanoparticles

  • Methods Article
  • Published:
Drug Delivery and Translational Research Aims and scope Submit manuscript

Abstract

This study reports scale-up and shelf-stability of curcumin encapsulated poly(lactic acid-co-glycolic acid) (PLGA) nanoparticles. The curcumin encapsulated PLGA nanoparticles were prepared by emulsification solvent evaporation/diffusion, and large quantities were made by varying the homogenisation time (5, 15 and 30 min). The particle size decreased as the homogenisation duration increased from 5 to 30 min, and the particles were spherical as confirmed by atomic force microscopy. For the large-scale preparations, the mean particles size was found to be 288.7 ± 3.4 (polydispersity index 0.15 ± 0.01) with curcumin entrapment 52.5 ± 4.3 %, which were comparable to the lab-scale preparations. The curcumin encapsulated nanoparticles were freeze-dried using sucrose (5 %, w/v) as a cryoprotectant. The freeze-dried nanoparticles were subjected to 6-month stability study as per the International Conference on Harmonisation guideline at room temperature and refrigerated storage conditions. Intermediate sampling was done (monthly), and the nanoparticles were thoroughly characterised for particle size, entrapment efficiency, surface morphology and crystallinity, which were compared to fresh preparations. The curcumin encapsulated PLGA nanoparticles were found to be stable at refrigerated as well as room temperature storage test conditions indicated by their particle characteristics. X-ray diffraction results confirm amorphous nature of curcumin on nano-encapsulation that stays intact after freeze drying and 6-month stability testing. Together these data offer possibility of producing large quantities of polymer nanoparticles that are suitable for room as well as refrigerated storage conditions opening up possibilities to conduct repeated dosings in a chronic setting or regulatory toxicology studies of such nanomedicines.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Kreuter J. Nanoparticles—a historical perspective. Int J Pharm. 2007;331:1–10.

    Article  PubMed  CAS  Google Scholar 

  2. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2:751–60.

    Article  PubMed  CAS  Google Scholar 

  3. LaVan DA, McGuire T, Langer R. Small-scale systems for in vivo drug delivery. Nat Biotechnol. 2003;21:1184–91.

    Article  PubMed  CAS  Google Scholar 

  4. Devadasu VR, Bhardwaj V, Kumar MNVR. Can controversial nanotechnology promise drug delivery? Chem Rev. 2013. doi:10.1021/cr300047q.

    PubMed  Google Scholar 

  5. Grama CN, Ankola DD, Kumar MNVR. Poly(lactide-co-glycolide) nanoparticles for peroral delivery of bioactives. Curr Opin Colloid Interface Sci. 2011;16:238–45.

    Article  CAS  Google Scholar 

  6. Holzera M, Vogel V, Mäntele W, Schwartz D, Haased W, Langer K. Physico-chemical characterisation of PLGA nanoparticles after freeze-drying and storage. Eur J Pharm Biopharm. 2009;72:428–37.

    Article  Google Scholar 

  7. Shaikh J, Ankola DD, Beniwal V, Singh D, Kumar MNVR. Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. Eur J Pharm Sci. 2009;37:223–30.

    Article  PubMed  CAS  Google Scholar 

  8. Kumar MNVR. Can efficient delivery systems leverage benefits of antioxidants leading to potential medicines? Drug Discov Today. 2012;17:407–8.

    Article  Google Scholar 

  9. Devadasu VR, Ankola DD, Bhardwaj V, Sahana DK, Kumar MNVR. Role of antioxidants in prophylaxis and therapy: a pharmaceutical perspective. J Control Release. 2006;113:189–207.

    Article  Google Scholar 

  10. Burgos-Moron E, Calderon-Montano JM, Salvador J, Robles A, Lopez-Lazaro ML. The dark side of curcumin. Int J Cancer. 2010;126:1771–5.

    PubMed  CAS  Google Scholar 

  11. Devadasu VR, Wadsworth RM, Kumar MNVR. Tissue localization of nanoparticles is altered due to hypoxia resulting in poor efficacy of curcumin nanoparticles in pulmonary hypertension. Eur J Pharm Biopharm. 2012;80:578–84.

    Article  PubMed  CAS  Google Scholar 

  12. Devadasu VR, Wadsworth RM, Kumar MNVR. Protective effects of nanoparticulate coenzyme Q10 and curcumin on free radical damage in streptozotocin-induced diabetic rats: a possible remedy to diabetic complications. Drug Deliv Transl Res. 2011;1:1448–55.

    Article  Google Scholar 

  13. Muthenna P, Suryanarayana P, Gunda SK, Petrash JM, Reddy GB. Inhibition of aldose reductase by dietary antioxidant curcumin: mechanism of inhibition, specificity and significance. FEBS Lett. 2009;583:3637–42.

    Article  PubMed  CAS  Google Scholar 

  14. Lin YG, Kunnumakkara AB, Nair A, Merritt WM, Han LY, Armaiz-Pena GN, et al. Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway. Clin Cancer Res. 2007;13:3423–30.

    Article  PubMed  CAS  Google Scholar 

  15. http://www.clinicaltrials.gov/ct2/results?term=curcumin&Search=Search

  16. Kundu P, Mohanty C, Sahoo SK. Antiglioma activity of curcumin-loaded lipid nanoparticles and its enhanced bioavailability in brain tissue for effective glioblastoma therapy. Acta Biomater. 2012;8:2670–87.

    Article  PubMed  CAS  Google Scholar 

  17. Chun YS, Bisht S, Chenna V, Pramanik D, Yoshida T, Hong SM, et al. Intraductal administration of a polymeric nanoparticle formulation of curcumin (NanoCurc) significantly attenuates incidence of mammary tumors in a rodent chemical carcinogenesis model: implications for breast cancer chemoprevention in at-risk populations. Carcinogenesis. 2012;33:2242–9.

    Article  PubMed  CAS  Google Scholar 

  18. Ranjan AP, Mukerjee A, Helson L, Vishwanatha JK. Scale up, optimization and stability analysis of curcumin C3 complex-loaded nanoparticles for cancer therapy. J Nanobiotechnol. 2012;10:38–56.

    Article  CAS  Google Scholar 

Download references

Acknowledgments

The authors are thankful to the Cancer Research UK Formulation Unit, SIPBS for permitting the use of ICH stability test chambers. Partial financial support by Cunningham Trust in the form of research grant (ACC/KWF/CT10/01) to MNVRK is acknowledged. C. N. Grama is grateful to University of Strathclyde for partial financial support towards her PhD studies. The authors acknowledge the instrument support from the Engineering and Physical Sciences Research Council (grant EP/E036244/1). Thanks are due to Vishal Raval for helping with XRD analysis.

Conflict of interest

Charitra N. Grama, Vinod P. Venkatpurwar, Dimitrios A. Lamprou and M. N.V. Ravi Kumar declare that they have no conflict of interest.

This article does not contain any studies with human or animal subjects.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to M. N. V. Ravi Kumar.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Grama, C.N., Venkatpurwar, V.P., Lamprou, D.A. et al. Towards scale-up and regulatory shelf-stability testing of curcumin encapsulated polyester nanoparticles. Drug Deliv. and Transl. Res. 3, 286–293 (2013). https://doi.org/10.1007/s13346-013-0150-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13346-013-0150-2

Keywords

Navigation